1. Home
  2. EARN vs SABS Comparison

EARN vs SABS Comparison

Compare EARN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.53

Market Cap

200.3M

Sector

Real Estate

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.68

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
SABS
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.3M
181.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
EARN
SABS
Price
$5.53
$3.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$5.88
$9.80
AVG Volume (30 Days)
329.7K
311.5K
Earning Date
02-18-2026
11-13-2025
Dividend Yield
17.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
$114,698.00
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$1.00
52 Week High
$6.82
$6.60

Technical Indicators

Market Signals
Indicator
EARN
SABS
Relative Strength Index (RSI) 66.67 47.75
Support Level $5.23 $3.56
Resistance Level $5.39 $4.19
Average True Range (ATR) 0.10 0.22
MACD 0.02 -0.03
Stochastic Oscillator 91.95 28.15

Price Performance

Historical Comparison
EARN
SABS

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: